7:00 AM – 7:30 AM Breakfast and Registration
7:30 AM – 7:45 AM Welcome and Program Overview
7:45 AM – 8:30 AM Clinical Discussion 1: Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
8:30 AM – 9:15 AM Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM Final Thoughts and Audience Question and Answer
Date / Time
Marriott Marquis Atlanta
Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Eunice S. Wang, MD
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with AML.
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
- Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
- Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
- Assess the available evidence to optimally integrateimmunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
- Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
- Manage treatment-related toxicities associated with novel therapeutics
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.5 contact hours.
Continuing Pharmacy Education
NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-0000-21-099-L01-P.
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.